How to buy Intersect ENT stock

Intersect ENT, Inc is a medical devices business based in the US. Intersect ENT shares (XENT) are listed on the NASDAQ and all prices are listed in US Dollars. Intersect ENT employs 406 staff and has a trailing 12-month revenue of around 0.00.

Intersect ENT share price

Use our graph to track the performance of XENT stocks over time.

Intersect ENT shares at a glance

• Key figures

Information last updated 2021-04-22.

52-week range	$10.72 - $26.98
50-day moving average	$20.69
200-day moving average	$21.00
Wall St. target price	$23.71
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.13

Buy Intersect ENT shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Intersect ENT stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Intersect ENT, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Intersect ENT financials

Revenue TTM	$80.6 million
Gross profit TTM	$57.1 million
Return on assets TTM	-18.9%
Return on equity TTM	-78.15%
Profit margin	-89.78%
Book value	$2.04
Market capitalisation	$680.5 million

TTM: trailing 12 months

Shorting Intersect ENT shares

There are currently 901,889 Intersect ENT shares held short by investors – that's known as Intersect ENT's "short interest". This figure is 8.5% down from 985,765 last month.

There are a few different ways that this level of interest in shorting Intersect ENT shares can be evaluated.

Intersect ENT's "short interest ratio" (SIR)

Intersect ENT's "short interest ratio" (SIR) is the quantity of Intersect ENT shares currently shorted divided by the average quantity of Intersect ENT shares traded daily (recently around 243096.76549865). Intersect ENT's SIR currently stands at 3.71. In other words for every 100,000 Intersect ENT shares traded daily on the market, roughly 3710 shares are currently held short.

However Intersect ENT's short interest can also be evaluated against the total number of Intersect ENT shares, or, against the total number of tradable Intersect ENT shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Intersect ENT's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Intersect ENT shares in existence, roughly 30 shares are currently held short) or 0.0276% of the tradable shares (for every 100,000 tradable Intersect ENT shares, roughly 28 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Intersect ENT.

Find out more about how you can short Intersect ENT stock.

Intersect ENT share dividends

We're not expecting Intersect ENT to pay a dividend over the next 12 months.

Have Intersect ENT's shares ever split?

Intersect ENT's shares were split on a 1:4 basis on 10 July 2014. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Intersect ENT shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Intersect ENT shares which in turn could have impacted Intersect ENT's share price.

Intersect ENT share price volatility

Over the last 12 months, Intersect ENT's shares have ranged in value from as little as $10.72 up to $26.98. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intersect ENT's is 1.61. This would suggest that Intersect ENT's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Intersect ENT overview

Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL and PROPEL Mini, which are steroid releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009.

Frequently asked questions

• What percentage of Intersect ENT is owned by insiders or institutions?

  Currently 3.137% of Intersect ENT shares are held by insiders and 93.698% by institutions.

• How many people work for Intersect ENT?

  Latest data suggests 406 work at Intersect ENT.

• When does the fiscal year end for Intersect ENT?

  Intersect ENT's fiscal year ends in December.

• Where is Intersect ENT based?

  Intersect ENT's address is: 1555 Adams Drive, Menlo Park, CA, United States, 94025

• What is Intersect ENT's ISIN number?

  Intersect ENT's international securities identification number is: US46071F1030

• What is Intersect ENT's CUSIP number?

  Intersect ENT's Committee on Uniform Securities Identification Procedures number is: 46071F103